Sarepta rises as 3‑year data shows gene therapy slows decline in muscle‑wasting disease

Shares of genetic medicine maker Sarepta Therapeutics SRPT.O rise 8% to $22.72 premarket

Co saysits Elevidys gene therapy slowed Duchenne muscular dystrophy progression by 70% or more on key movement tests over three years vs an external control group

 Co says boys treated at ages 4–7 maintained motor function through age 9, with average scores on a standard movement scale staying above baseline

 SRPT's Elevidys is being developed for Duchenne muscular dystrophy — a rare muscle‑wasting disease where boys progressively lose muscle strength and eventually the ability to walk, per co

Trial tested Elevidys against placebo in boys aged between 4 and 7 years who had not yet lost the ability to walk due to DMD, co says

Shares fell ~82% in 2025